[go: up one dir, main page]

WO2010063172A1 - Protéine hybride d'elp et ses utilisations - Google Patents

Protéine hybride d'elp et ses utilisations Download PDF

Info

Publication number
WO2010063172A1
WO2010063172A1 PCT/CN2009/072395 CN2009072395W WO2010063172A1 WO 2010063172 A1 WO2010063172 A1 WO 2010063172A1 CN 2009072395 W CN2009072395 W CN 2009072395W WO 2010063172 A1 WO2010063172 A1 WO 2010063172A1
Authority
WO
WIPO (PCT)
Prior art keywords
elp
protein
fusion protein
fusion
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2009/072395
Other languages
English (en)
Chinese (zh)
Inventor
徐安龙
蓝东明
黄光瑞
王磊
陈尚武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Publication of WO2010063172A1 publication Critical patent/WO2010063172A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the invention relates to the field of biotechnology, and in particular to an ELP fusion protein and application thereof. Background technique
  • One of the most direct research methods is to recombinantly express the gene under study, obtain the corresponding protein, conduct physiological and biochemical activity research and analyze its structural biology to clarify its function. Due to the differences in species genes, not all genes can be successfully expressed. Genes are not expressed, protein expression is low or the expressed protein is unstable to form insoluble inclusion bodies. These phenomena are frequently found in heterologous expression systems, particularly in prokaryotic expression systems. With the development of DNA recombination technology, the gene of interest can be fused with the gene expressing the affinity tag, and then cloned and expressed in the expression vector for fusion expression. These affinity tags can not only help the folded target protein to be folded, but also enhance the target protein.
  • affinity purification tags include Glutathione-S-Transferase (GST), Maltose-binding Protein (MBP), His tag and the like.
  • GST Glutathione-S-Transferase
  • MBP Maltose-binding Protein
  • His tag His tag
  • the fusion protein containing the corresponding protease cleavage site is cleaved by protease to separate the target protein from the affinity tagged protein, and the affinity is removed by further chromatography.
  • the target protein is obtained by labeling and protease.
  • Affinity chromatography is a very efficient separation method, and the purification protein can be purified in one step without knowing the physicochemical properties of the fusion protein.
  • This purification technique is widely used.
  • affinity chromatography separation techniques requires expensive affinity resins, and corresponding purification equipment, which limits the simultaneous expression of multiple proteins for high-throughput structural biology studies and high-throughput drug protein screening.
  • ELP heat-sensitive purified label elastin-like polypeptide
  • ELP When the temperature is lower than the transition temperature (Tt), ELP is highly soluble in the liquid phase. However, when the temperature is higher than Tt, the hydrophilic ELP dehydrates and agglomerates, and the ELP fusion protein also has This property, but it should be pointed out that when the phase transition occurs, only the ELP is coagulated and the foreign protein to be fused does not undergo denaturation or precipitation. Using this property of ELP, the ELP tag can be conveniently and quickly utilized to purify the ELP fusion protein, and chromatographic separation is eliminated during the purification process, avoiding expensive affinity resins and purification equipment, while concentrating and replacing the ELP fusion protein. The buffer also became very simple.
  • the aggregation of the ELP fusion protein is triggered by heating or increasing the salt ion concentration, and the ELP fusion protein is separated from the expression host protein by centrifugation, and the precipitated ELP fusion protein is re-dissolved with a low-salt low-temperature solution, and then centrifuged to remove insoluble
  • the protein is obtained to obtain an ELP fusion protein, and a more pure ELP fusion protein can be obtained by repeatedly triggering the precipitation, centrifugation and re-dissolution steps. This purification process is called Inverse Transition Cycling (ITC).
  • ITC Inverse Transition Cycling
  • Enzymes are highly efficient and specific biocatalysts. Various chemical reactions in living organisms are carried out under enzymatic catalysis, but free enzymes are very unstable in aqueous solution, and soluble enzymes generally only catalyze in one time. At the same time, enzymes are proteins to heat, high ion concentration, Strong acids, strong bases and some organic solvents are not stable enough to be easily deactivated and reduce their catalytic ability. These disadvantages greatly limit the wide application of enzymatic reactions.
  • the Immobilized enzyme technology that emerged in the 1960s overcomes these shortcomings of free enzymes, and the enzymes can be recycled and reused, making it one of the most active research areas in biotechnology.
  • the immobilization method of the enzyme can be broadly classified into four types: an adsorption method, a covalent coupling method, a crosslinking method, and an embedding method.
  • Adsorption method refers to the secondary bond phase between the surface of the carrier and the surface of the enzyme.
  • the method of interaction to achieve enzyme immobilization can be further divided into physical adsorption and ion exchange adsorption according to the characteristics of the adsorbent.
  • the method has the advantages of operating the tube, mild conditions and repeated use of the adsorbent, but also has the disadvantages of weak adsorption force, easy to desorb off under unsuitable pH, high salt concentration, high substrate concentration and high temperature conditions.
  • the covalent coupling method combines the active non-essential side chain group of the enzyme with the functional group of the carrier through a covalent bond, so that it exhibits good stability and is beneficial to the continuous use of the enzyme, and is currently the most active application and research.
  • One type of enzyme immobilization method but the covalent coupling reaction easily denatures the enzyme and inactivates it.
  • the cross-linking method is a method of immobilizing an enzyme by cross-linking between enzyme molecules using a bifunctional or multifunctional group reagent, which is more likely to inactivate the enzyme.
  • the embedding method includes grid embedding, micro-encapsulation and liposome entrapment.
  • the enzyme itself does not participate in the chemical binding reaction, so that high enzyme activity recovery can be obtained, and the disadvantage is that it is not applicable. It is used for mass transfer of high molecular weight substrates and for column reaction systems, and often has problems such as diffusion limitations. Moreover, the cost of the immobilized enzyme is too high, and the substrate of the macromolecule is not easy to use. The deficiencies exhibited by the various methods of immobilizing enzymes described above limit their widespread use. Summary of the invention
  • step (3) allowing the mixture of step (2) to interact, wherein fusion protein B degrades fusion protein A into an ELP-containing fusion partner and a target protein;
  • the nucleotide sequence of the above ELP monomer is shown in SEQ ID N0.1.
  • the above ELP is a tetramer, a pentamer, a hexamer, a heptamer, an octamer or a nine of the ELP monomers. Polymer.
  • the above fusion protein B includes an ELP-3C or ELP-SUMO (small ubiquitin-related modifier) protease.
  • step (3) allowing the mixture of step (2) to interact, wherein fusion protein D degrades fusion protein C into an ELP-containing fusion partner and a target protein;
  • the fusion partner of ELP refers to an ELP-containing protein in addition to a target protein in a fusion protein.
  • the nucleotide sequence of the above ELP monomer is shown in SEQ ID N0.1.
  • the above ELP is a tetramer, a pentamer, a hexamer, a heptamer, an octamer or a hexamer of an ELP monomer.
  • the above fusion protein D includes an ELP-3C or ELP-SUMO (small ubiquitin-related modifier) protease.
  • a third object of the present invention is to provide an ELP-containing fusion protein comprising an elastin-like polypeptide (ELP) and at least one protein or polypeptide of interest, which can be formed with ELP.
  • ELP elastin-like polypeptide
  • nucleotide sequence of the monomer of the above elastin-like polypeptide is shown in SEQ ID N0.1.
  • the above elastin-like polypeptide includes a tetramer, a pentamer, a hexamer, a heptamer, and a hexa Polymer or 9-mer.
  • a fourth object of the present invention is to provide a method for expressing a purified fusion protein containing ELP, comprising the steps of:
  • the obtained aggregate is an ELP-containing fusion protein.
  • the nucleotide sequence of the monomer of the ELP is shown in SEQ ID N0.1.
  • the ELP is a tetramer, a pentamer, a hexamer, a heptamer, an octamer or a hexamer of an ELP monomer.
  • the fusion protease E includes an ELP-3C or ELP-SUMO (small ubiquitin-related modifier) protease.
  • a fifth object of the present invention is to provide a kit for purification of protein expression, the kit comprising an ELP-containing plasmid for preparing a fusion protein F and a fusion protein G, the fusion
  • the protein G contains a protein or polypeptide of interest, and the fusion protein F can be digested to obtain a protein or polypeptide of interest.
  • the fusion protein F includes an ELP-3C or ELP-SUMO (small ubiquitin-related modifier) protease.
  • the fusion protein F is capable of cleaving the fusion protein G into an ELP and a target protein.
  • a sixth object of the present invention is to provide a recyclable enzyme having an immobilized enzyme property, which is a fusion protease comprising ELP, which can be in a dissolved or precipitated state depending on temperature or salt ion concentration.
  • the nucleotide sequence of the monomer of the ELP is shown in SEQ ID N0.1.
  • the ELP is a tetramer, a pentamer, a hexamer, a heptamer, an octamer or a hexamer of an ELP monomer.
  • the fusion protease includes an ELP-3C or ELP-SUMO (small ubiquitin-related modifier) protease.
  • a seventh object of the present invention is to provide a method for performing cyclic enzymatic purification using a protease comprising ELP, comprising the steps of:
  • the substrate in the step (1) is an ELP fusion protein containing a protein of interest.
  • the monomer of the artificially synthesized ELP is the pentapeptide "Val-Pro-Gly-Xaa-Gly" (Xaa is an arbitrary amino acid other than the pro amino acid), and in the present invention, the ELP contains the tetramer of the ELP monomer, and the pentapolymer Various types, such as body, hexamer, heptamer, octamer, and 9-mer, change the conditions of ELP or ELP-containing fusion protein, including at least one of temperature, salt ion concentration, and pH. Conditions, ELP or ELP-containing fusion proteins can be precipitated or dissolved in different states, and when the original conditions are restored, the ELP or ELP-containing fusion protein can return to its original state.
  • the method for expressing a purified protein of interest, the unlabeled recombinant protein, and the target protein involved in the cyclic digestion purification using a protease containing ELP include a relatively broad protein. Specifically, it includes viral proteins, bacterial proteins, yeast expressed proteins, mammalian proteins, and the like.
  • ELP - 3C and ELP - SUMO are only two specific examples, and of course, are not limited to these two types, and enzyme enzymes having enzymatic activity are included in the scope of the present invention.
  • These enzymatically active proteases act on the ELP-containing fusion protein containing the corresponding cleavage site, thereby cleaving the substrate into the target protein and the ELP fusion partner; and these digested fusion proteins cannot act on themselves.
  • the ELP fusion partner refers to a protein other than the target protein containing ELP, and the ELP fusion partner and the target protein have an enzyme cleavage site, which can be digested into a target protein and an ELP fusion partner.
  • the expression vector referred to in the present invention has a general meaning, that is, a vector containing a promoter sequence, which is capable of efficiently promoting the transcription of the inserted target gene, and then translating the protein product encoded by the inserted gene.
  • the promoter of the expression vector is usually homologous to its receptor, such as an expression vector containing E. coli as a receptor, the promoter of which is derived from the E. coli system, and the promoter expressed in the vaccinia virus is derived from the vaccinia virus.
  • the vector is mainly a plasmid or a virus, including plant viruses, animal viruses, and phage.
  • plasmid vectors carrying Escherichia coli such as pQE, pMAL, pUC, etc., and lambda phage and Escherichia coli artificial chromosome (BAC), Yeast-based yeast artificial chromosome (YAC) and pRS series yeast plasmid vector, pcDNA series plasmid and pEGFP series plasmid hosted on mammalian cells (animal/E. coli shuttle plasmid).
  • the prokaryotic expression vector is usually a plasmid, and the typical expression vector has the following components: a coding sequence for selection of a marker, a promoter for controllable transcription, a transcriptional regulatory sequence (transcription terminator, ribosome binding site), a multi-restriction enzyme digestion Site linker and sequences autonomously replicated in the host.
  • the pET system is the most powerful system for expressing recombinant proteins in E. coli.
  • the gene of interest was cloned into the pET plasmid vector and subjected to strong transcriptional and translational (selective) signals by the phage T7; expression was induced by T7 RNA polymerase provided by the host cell.
  • the system allows the gene of interest to be completely silent without transcription.
  • Cloning of the gene of interest with a host strain that does not contain T7 RNA polymerase avoids plasmid instability due to possible toxicity of the protein of interest to the host cell.
  • expression of the protein of interest can be initiated by two methods: infecting the host cell with a lambda CE6 phage bearing T7 RNA polymerase controlled by the A pL and pi promoters, or transferring the plasmid into An expression cell with a T7 RNA polymerase gene under the control of lacUV5.
  • expression can be initiated by the addition of IPTG to the bacterial culture medium.
  • the two T7 promoters, as well as a variety of host cells with different levels of inhibition of background expression constitute an extremely flexible and efficient system for optimal expression of various proteins of interest.
  • the viral vector is a viral particle that allows the foreign gene to enter the cell by interaction of the viral envelope protein with the host cell membrane.
  • the vector used in the present invention includes commonly used viral vectors, including adenovirus, adeno-associated virus, retrovirus, semliki forest virus (sFv) vector and the like.
  • sFv semliki forest virus
  • the application of baculovirus vectors to mammalian cells has received much attention in recent years because of its unique advantages over other viral vectors, such as the large production of viral particles by insect cells; A mammalian cell, but has no replication ability in the cell, and has high biosafety; it can insert a foreign gene of up to 38 kb.
  • MNPV autogra-phacalifornica multi-nuclear polyhedrosis virus
  • AcMNPV autogra-phacalifornica multi-nuclear polyhedrosis virus
  • the virus It is the prototype of the baculoviridae Baculoviridae. It is a large, double-stranded DNA virus with a coat that can infect more than 30 lepidopteran insects and is widely used as a vector for gene expression systems.
  • the AcNPV virus is used as an expression vector for a foreign gene, and a recombinant virus is usually constructed by replacing the polyhedrin gene with a foreign gene by a method of homologous recombination in vivo. Since the polyhedrin gene promoter began transcription and translation 18 to 24 hours after infection, it lasted for 70 hours.
  • baculoviruses as expression vectors are mainly NP ⁇ (bombyx moil, BmNP ⁇ ) from silkworm. Since the in vivo system of silkworm larvae is suitable for large-scale production and production of foreign proteins, and has low cost, it has a good application prospect.
  • Pichia pastoris expression system In the yeast expression system, the Pichia pastoris expression system is considered to be one of the most effective expression systems.
  • the Pichia pastoris expression system has a variety of secretory expression plasmids, and many proteins are highly secreted and expressed in Pichia pastoris. Extracellular expression requires the addition of a signal peptide sequence at the N-terminus of the foreign protein to direct the recombinant protein into the secretory pathway.
  • the present invention has the following beneficial effects:
  • the present invention utilizes the reverse temperature phase transition characteristic of ELP to provide a series of ELP fusion proteins which can be used in protein expression and purification as well as recyclable enzymes having immobilized enzyme properties.
  • the ELP fusion protein has the characteristics of a solid phase enzyme, which facilitates continuous production and automation for industrial mass production.
  • Figure 1 shows the induced expression and purification of ELP-3C protease and its SDS-PAGE electrophoresis for purification of GST protein.
  • M protein molecular weight standard
  • 1 total bacterial protein induced by ELP-3C protease
  • 2 cleavage supernatant induced by ELP-3C protease
  • 3 centrifugation supernatant after precipitation of ELP-3C protease by salt
  • 4 purification Post-ELP-3C protease
  • 5 purified GST-ELP
  • 6 ELP-3C protease digested GST-ELP
  • 7 pre-cleaved product
  • 8 purified GST.
  • Figure 2 is an SDS-PAGE electropherogram showing the optimal digestion concentration of the GST-ELP fusion protein by ELP-3C protease digestion.
  • Figure 3 is a SDS-PAGE electropherogram of the purification of GFP protein by ELP-3C protease.
  • M protein molecular weight standard
  • 1 total bacterial protein induced by ELP-GFP
  • 2 cleavage supernatant induced by ELP-GFP
  • 3 centrifugation supernatant after precipitation of ELP-GFP by salt
  • 4 ELP after purification - GFP
  • 5 ELP-3C protease digests ELP-GFP
  • 6 pre-cleaved product
  • 7 purified GFP.
  • Figure 4 shows the purified GFP protein detected under a fluorescence microscope.
  • Figure 5 is a SDS-PAGE electropherogram of the purification of MBP protein by ELP-3C protease.
  • M protein molecular weight standard
  • 1 total bacterial protein induced by ELP-MBP
  • 2 cleavage supernatant induced by ELP-MBP expression
  • 3 centrifugation supernatant after precipitation of ELP-MBP by salt
  • 4 ELP after purification - MBP
  • 5 ELP-3C protease digestion of ELP-MBP
  • 6 precipitation of the product
  • 7 purified MBP.
  • Figure 6 is a SDS-PAGE electropherogram of purification of TRX protein by ELP-3C protease.
  • M protein molecular weight standard
  • 1 total bacterial protein induced by ELP-TRX
  • 2 cleavage supernatant induced by ELP-TRX expression
  • 3 centrifugation supernatant after precipitation of ELP-TRX by salt
  • 4 ELP after purification -TRX
  • 5 ELP-3C protease digestion ELP-TRX
  • 6 precipitation digestion product
  • 7 purified TRX.
  • Figure 7 is a SDS-PAGE electropherogram of the PEG protein purified by continuous digestion.
  • 1 The first ELP-3C protease cleaves ELP-GFP-purified GFP;
  • 2 The second ELP-3C protease cleaves ELP-GFP-purified GFP;
  • 3 The third ELP-3C protease cleaves ELP -GFP purified after GFP;
  • 4 GFP after encapsulation of ELP-GFP by the fourth ELP-3C protease;
  • 5 GFP after encapsulation of ELP-GFP by the fifth ELP-3C protease; 6: sixth time ELP-3C protease cleaves GFP after purification of ELP-GFP.
  • the ELP gene was synthesized according to the method reported by Meyer and Chilkoti et al. in 1999 (Meyer, DE, and Chilkoti, A. 1999. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol 17: 1112-1115.)
  • the nucleotide sequence ⁇ 'J is shown in SEQ ID NO. After digestion with the Ecorl and C-terminal Hindlll of the ELP gene, the corresponding restriction sites in the commercial prokaryotic expression vector pET23a were cloned to form a pET23a-ELP vector.
  • the pET23a-ELP plasmid was transformed into Escherichia coli DH5a strain, and the pET23a-ELP plasmid was extracted after culture expression.
  • the 3C protease gene was synthesized according to the gene sequence of human rhinovirus 3C protease (Accession No.: M12168) published in genbank in NCBI, and its nucleotide sequence is shown in SEQ ID N0.2, and cloned into pbluscript vector.
  • the pbluscript-3C vector was formed.
  • the pbluscript-3C plasmid was transformed into Escherichia coli DH5a strain, and the pbluscript-3C plasmid was extracted after culture expression.
  • pbluscript-3C was digested with Hindl and C-terminal Notl endonucleases at the N-terminus of the 3C protease gene, and the purified 3C gene fragment was cloned into the corresponding restriction site of the pET23a-ELP vector, and the 3C protease gene was located in the ELP gene.
  • the ELP-3C protease expression vector pET23a-ELP-3C was obtained.
  • the constructed expression vector pET23a-ELP-3C was transformed into E.co/.BL21 by CaCl 2 method according to the method of Sambrook (Sambrook, et al. 1989, Molecular doing. Cold Spring Harbor Labroratory Press. USA). DE3) strain, the transformed strain was cultured in LB medium containing ampicillin (100 g/mL).
  • a single colony of the expression host strain BL21 (DE3) containing the recombinant plasmid pET23a-ELP-3C was inoculated into an Amp+ LB liquid-enriched medium, and cultured at 37 ° C for 225 rpm for 12 hours as a seed fungus. Seeding The bacterium was inoculated in fresh Amp + TB medium at a ratio of 1:100, and cultured at 37 ° C with vigorous shaking until the OD 600 was about 1.0, and the temperature was adjusted to 18 ° C for 24 hours. 100 ml of the induced bacterial liquid was centrifuged and centrifuged at 5000 rpm for 5 minutes.
  • the cells were resuspended in 8 ml of ice-cold PBS, and then ultrasonically lysed, with a power of 200 W and sonication for 15 minutes.
  • the lysate was centrifuged at 12000 g for 10 minutes at 4 ° C to remove insoluble bacterial proteins.
  • Solid NaCl was added to the centrifugation supernatant and dissolved, and the solution concentration was 2 M.
  • the cleavage supernatant was changed from clarification to turbidity at room temperature. After the turbid lysate supernatant was centrifuged at room temperature for 5 minutes at high speed, the supernatant was removed.
  • the precipitate was resuspended by adding pre-cooled PBS, the precipitate was blown off and placed on ice until all the precipitates were dissolved.
  • This protein solution was centrifuged at 12000 g for 5 minutes at 4 ° C to remove the insoluble precipitate.
  • the supernatant obtained by centrifugation was repeatedly salted to agglomerate the protein, centrifuged, the protein precipitate was dissolved, and the step of insoluble precipitation was removed by centrifugation until all the hybrid proteins were removed to obtain a purer target protein (see Fig. 1).
  • a single colony of the pGEX-ELP expression host strain BL21 (DE3) containing the recombinant plasmid was inoculated into an Amp+ LB liquid-enriched medium, and cultured at 37 ° C for 225 rpm for 12 hours as a seed fungus.
  • the seed bacteria were inoculated into fresh Amp+ LB rich medium at a ratio of 1:100, and cultured at 37 °C with vigorous shaking until O.D. 600 was about 1.0, 0.5 mM IPTG was added, and expression was induced at 37 ° C for 4 hours.
  • the solution was lysed by adding solid NaCl to a concentration of 2 M, triggering GST-ELP agglutination and centrifuging to precipitate, using 3C digestion buffer (50 mM Tris, 150 mM NaCl, ImM EDTA, pH 8.0, ImM DTT). Dissolve. ELP-3C protease was added at 1:100 and digested at 5 °C for 16 hours. After digestion, solid NaCl was added to make the solution concentration 2 M, and the ELP and ELP-3C proteases were triggered to agglutinate and centrifuged to remove. The supernatant was collected for purification of GST protein (see Figure 1).
  • 3C digestion buffer 50 mM Tris, 150 mM NaCl, ImM EDTA, pH 8.0, ImM DTT.
  • ELP-3C protease was added at 1:100 and digested at 5 °C for 16 hours. After digestion, solid NaCl was added to make the solution concentration 2 M, and
  • Example 4 Enzymatic digestion of ELP-3C protease The optimal digestion concentration of GST-ELP fusion protein
  • the ELP-GFP was triggered to agglutinate and centrifuged to precipitate, and 3C digestion buffer (50 mM Tris, 150 mM NaCl, ImM EDTA, pH 8.0, ImM DTT) was used. Dissolve.
  • the ELP-3C protease was added at 1:100 and digested at 5 °C for 16 hours. After digestion, solid NaCl was added to a solution concentration of 2 M, and ELP and ELP-3C proteases were triggered to agglutinate and removed by centrifugation. The supernatant was collected for purification of GFP protein (see Figure 3). When the purified GFP protein was observed under a fluorescence microscope, significant fluorescence was detected (see Figure 4).
  • the single colony of the expression host strain BL21 (DE3) containing the recombinant plasmid pET23a-ELP-MBP was inoculated into Amp+ LB liquid-enriched medium, and cultured at 37 ° C for 225 rpm for 12 hours as a seed fungus.
  • the seed bacteria were inoculated in fresh Amp + TB medium at a ratio of 1:100, and cultured vigorously at 37 ° C until O.D. 600 was about 1.0, and the temperature was adjusted to 18 ° C for 24 hours. After the bacteria were collected, the solution was lysed, and the solution concentration was 2M by adding solid NaCl.
  • the ELP-MBP was triggered to agglutinate and centrifuged to precipitate.
  • the 3C digestion buffer 50 mM Tr, 150 mM NaCl, ImM EDTA, pH 8.0, ImM DTT was used. ) Dissolve. ELP-3C protease was added at 1:100 and digested at 5 °C for 16 hours. After digestion, solid NaCl was added to make the solution concentration 2 M, and the ELP and ELP-3C proteases were triggered to agglutinate and removed by centrifugation. The supernatant was collected as purified MBP protein (see Figure 5).
  • the single colony of the expression host strain BL21 (DE3) containing the recombinant plasmid pET23a-ELP-TRX was inoculated into an Amp+ LB liquid-enriched medium, and cultured at 37 ° C for 225 rpm for 12 hours as a seed fungus.
  • the seed bacteria were inoculated in fresh Amp + TB medium at a ratio of 1:100, and cultured at 37 ° C with vigorous shaking until the OD 600 was about 1.0, and the temperature was adjusted to 18 ° C for 24 hours.
  • the solution was lysed by adding solid NaCl to a concentration of 2 M, triggering GST-GFP to agglutinate and centrifuging to precipitate, using 3C digestion buffer (50 mM Tri, 150 mM NaCl, ImM EDTA, pH 8.0, ImM). DTT) is dissolved.
  • 3C digestion buffer 50 mM Tri, 150 mM NaCl, ImM EDTA, pH 8.0, ImM). DTT
  • the ELP-3C protease was added at 1:100 and digested at 5 °C for 16 hours. Add solid after digestion NaCl was brought to a solution concentration of 2 M, and ELP and ELP-3C proteases were triggered to agglutinate and removed by centrifugation. The supernatant was collected as purified TRX protein (see Figure 6).
  • the ELP-GFP protein was digested with 1 mg of ELP-GFP protein, and ELP-3C protease was added at a mass ratio of ELP-3C:ELP-GFP of 1:100. After digesting at 20 °C for 4 hours, solid NaCl was added to digest the solution to a concentration of 2 M, and the mixture was centrifuged at room temperature for 5 minutes at high speed, and the supernatant sample was retained. The pellet was resuspended in a digestion buffer solution (50 mM Tr, 150 mM NaCl, 1 mM EDTA, pH 8.0, ImM DTT) containing 1 mg of ELP-GFP protein, and continuously soaked to dissolve the precipitate, and then continued for 20°.
  • a digestion buffer solution 50 mM Tr, 150 mM NaCl, 1 mM EDTA, pH 8.0, ImM DTT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une protéine hybride comprenant ELP, et ses utilisations, ainsi qu’une protéase marquée par ELP qui peut servir d’enzyme utilisée pour le recyclage et présente une caractéristique d’enzyme immobilisée, et ses utilisations. Par exemple, le procédé de purification ou de séparation faisant appel à une caractéristique de transition de phase d'ELP consiste à mettre en contact la protéine hybride d'ELP comportant un site de clivage de protéase avec une enzyme marquée par ELP, puis à soumettre le mélange destiné au clivage à une transition de phase médiée par un changement de température, de pH ou de concentration d'ions sels pour récupérer la protéine d'intérêt dans ledit mélange.
PCT/CN2009/072395 2008-12-02 2009-06-23 Protéine hybride d'elp et ses utilisations Ceased WO2010063172A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2008102196035A CN101418290A (zh) 2008-12-02 2008-12-02 一种高效的elp融合蛋白酶及其制备和应用
CN200810219603.5 2008-12-02

Publications (1)

Publication Number Publication Date
WO2010063172A1 true WO2010063172A1 (fr) 2010-06-10

Family

ID=40629293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/072395 Ceased WO2010063172A1 (fr) 2008-12-02 2009-06-23 Protéine hybride d'elp et ses utilisations

Country Status (2)

Country Link
CN (2) CN101418290A (fr)
WO (1) WO2010063172A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101418290A (zh) * 2008-12-02 2009-04-29 中山大学 一种高效的elp融合蛋白酶及其制备和应用
CN102432668A (zh) * 2011-11-25 2012-05-02 华侨大学 一种能对目标重组蛋白进行离心法快速分离纯化的方法
CN103513039B (zh) * 2013-07-10 2015-12-23 广州美格生物科技有限公司 一种利用定向肽库检测蛋白质与其他分子相互作用的方法
CN104448004A (zh) * 2014-12-03 2015-03-25 华侨大学 一种融合抗菌肽及其制备方法
CN104725515B (zh) * 2015-03-20 2017-11-14 扬州大学 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用
CN106519040B (zh) * 2016-11-02 2020-03-27 南京大学 一种含肿瘤坏死因子相关凋亡诱导配体的融合蛋白和其制备方法及由该蛋白自组装的纳米粒
CN106591345A (zh) * 2016-12-26 2017-04-26 华侨大学 一种重组双酶分离纯化及固定化集成的方法
CN107083329B (zh) * 2017-05-17 2019-06-04 华侨大学 一种基于类弹性蛋白多肽的固定化酶反应器及其应用
CN108034670B (zh) * 2017-12-25 2021-03-30 大连大学 一种食源性大豆生物活性肽Lunasin的无柱式、低成本制备方法
CN110029115A (zh) * 2019-04-19 2019-07-19 河南牧业经济学院 编码天花粉蛋白的融合基因、其表达蛋白及其应用
CN111856024B (zh) * 2019-04-28 2022-01-28 清华大学 检测生物膜蛋白质间相互作用的方法及所用成套试剂
CN111979206B (zh) * 2019-05-24 2021-08-17 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法
CN111019962A (zh) * 2019-12-18 2020-04-17 南京理工大学 一种sod-elp融合蛋白及其制备方法
CN113292647B (zh) * 2021-07-28 2021-10-29 南京谷浦生物科技有限公司 一种igf-1的低成本制备方法及其应用
CN113461796A (zh) * 2021-08-04 2021-10-01 深圳晶蛋生物医药科技有限公司 一种重组sglt2蛋白及其应用
CN115838698A (zh) * 2022-12-12 2023-03-24 长春圣金诺生物制药有限公司 一种重组尿酸氧化酶的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074928A2 (fr) * 2001-03-20 2002-09-26 Ashutosh Chilkoti Peptides de fusion pouvant etre isoles par transition de phase
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
WO2008030968A2 (fr) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Compositions thérapeutiques peptidiques de fusion
CN101418290A (zh) * 2008-12-02 2009-04-29 中山大学 一种高效的elp融合蛋白酶及其制备和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
WO2002074928A2 (fr) * 2001-03-20 2002-09-26 Ashutosh Chilkoti Peptides de fusion pouvant etre isoles par transition de phase
WO2008030968A2 (fr) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Compositions thérapeutiques peptidiques de fusion
CN101418290A (zh) * 2008-12-02 2009-04-29 中山大学 一种高效的elp融合蛋白酶及其制备和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYE-JIN K. ET AL.: "Heterologous expression and optimized one-step separation oflevansucrase via elastin-like polypeptides tagging system", J. MICROBIOL. BIOTECHNOL., vol. 17, no. 11, 2007, pages 1751 - 1757 *
LIM D.W. ET AL.: "Improved non-chromatographic purification of a recombinant protein by cationic elastin-like polypeptides", BIOMACROMOLECULES, vol. 8, no. 5, 2007, pages 1417 - 1424 *

Also Published As

Publication number Publication date
CN101418290A (zh) 2009-04-29
CN101633946A (zh) 2010-01-27

Similar Documents

Publication Publication Date Title
WO2010063172A1 (fr) Protéine hybride d'elp et ses utilisations
CN113980112B (zh) 一种眼镜王蛇抗菌肽oh-cath30的表达载体和表达产物及其构建制备方法
US8759028B2 (en) Expression cassette, recombinant host cell and process for producing a target protein
WO2001053333A1 (fr) Procedes de purification et de filage de fibres aqueuses de soie d'araignee et autres proteines structurales
CN111349177B (zh) 一种融合抗菌肽cat的制备方法和应用
CN107446941A (zh) 基于自聚集短肽诱导的天蚕素a抗菌肽及其制备方法
WO2022253266A1 (fr) Procédé de purification de protéine recombinante
CN113321718A (zh) 昆虫cpcfc家族表皮蛋白，编码核苷酸序列及其应用
CN101319216A (zh) 重组家蚕抗菌肽cm4的生产和纯化方法
CN113004375B (zh) 一种高效介导重组多肽形成包涵体的小分子蛋白
WO2025055767A1 (fr) Procédé de purification de protéine
CN106834252A (zh) 一种高稳定型MazF突变体及其应用
CN106755042A (zh) 一种基于组合自剪切与蛋白支架的生物活性小肽制备方法
CN111269901A (zh) 一种环氧化物水解酶突变体及其应用
CN111349623B (zh) 9°n dna聚合酶突变体
CN108864273B (zh) 一种模拟人源性抗菌肽及其制备方法
CN114478725A (zh) 一种链霉亲和素突变体及其制备方法和应用
CN113025599A (zh) 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN110592054B (zh) 海马孵化酶基因及其编码蛋白和应用
CN1164749C (zh) 黄牛肠激酶催化亚基基因及其基因工程生产方法
CN112941058B (zh) 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN114560911B (zh) 一种抗真菌肽及其制备方法
CN113151227B (zh) 一种蛋白酶基因及其异源表达
WO2018047856A1 (fr) Protéine fusionnée, corps structural, agent de piégeage, méthode de piégeage, adn et vecteur
JP5875052B2 (ja) 有用タンパク質の高発現方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829956

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09829956

Country of ref document: EP

Kind code of ref document: A1